Literature DB >> 31655405

Altered resting-state functional connectivity of the insula in individuals with clinical high-risk and patients with first-episode schizophrenia.

Xian-Bin Li1, Lu-Bin Wang2, Yan-Bing Xiong1, Qi-Jing Bo1, Fan He1, Feng Li1, Wen-Peng Hou1, Yu-Jie Wen1, Xue-Qi Wang1, Ning-Bo Yang1, Zhen Mao1, Qian-Hong Dong1, Fei-Fei Zhang1, Rui Yang1, Di Wang1, Yu-Tao Xiang3, Yu-Yang Zhu2, Yi-Lang Tang4, Zheng Yang5, Chuan-Yue Wang6.   

Abstract

OBJECTIVES: Abnormalities in insular functional connectivity have been implicated in many clinical features of schizophrenia. The aim of this study was to determine to what degree such abnormalities occur in individuals with clinical high risk for psychosis (CHR), and whether which is associated with symptom severity.
METHODS: Resting-state fMRI data were collected from 47 healthy controls, 24 CHR individuals and 19 patients with first-episode schizophrenia. Using the posterior, dorsal and ventral insular subregions as separate seeds, we examined resting-state functional connectivity differences between different groups and the association between concurrent symptom severity and dysconnectivity.
RESULTS: Compared with healthy controls, both CHR individuals and schizophrenia patients showed hypoconnectivity between posterior insula (PI) and somatosensory areas, and between dorsal anterior insula (dAI) and putamen. Schizophrenia patients also showed dAI and ventral anterior insula(vAI) hyperconnectivity with visual areas relative to controls and CHR individuals. Correlation analysis revealed that dAI functional connectivity with superior temporal gyrus was positively correlated with positive symptoms of CHR, and vAI connectivity with dorsolateral prefrontal cortex was negatively correlated with the severity of the symptoms of first-episode schizophrenia.
CONCLUSIONS: Our findings suggest that insular functional dysconnectivity with the sensory cortex may be a system-level neural substrate preceding the onset of psychosis.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinical high-risk; Insula; Resting-state functional connectivity; Schizophrenia

Mesh:

Year:  2019        PMID: 31655405     DOI: 10.1016/j.psychres.2019.112608

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  5 in total

1.  Linking Salience Signaling With Early Adversity and Affective Distress in Individuals at Clinical High Risk for Psychosis: Results From an Event-Related fMRI Study.

Authors:  Zachary B Millman; Jason Schiffman; James M Gold; LeeAnn Akouri-Shan; Caroline Demro; John Fitzgerald; Pamela J Rakhshan Rouhakhtar; Mallory Klaunig; Laura M Rowland; James A Waltz
Journal:  Schizophr Bull Open       Date:  2022-06-17

2.  Application of Mass Multivariate Analysis on Neuroimaging Data Sets for Precision Diagnostics of Depression.

Authors:  Rositsa Paunova; Sevdalina Kandilarova; Anna Todeva-Radneva; Adeliya Latypova; Ferath Kherif; Drozdstoy Stoyanov
Journal:  Diagnostics (Basel)       Date:  2022-02-12

3.  Aberrant Resting-State Functional Brain Connectivity of Insular Subregions in Obstructive Sleep Apnea.

Authors:  Linghong Kong; Haijun Li; Yongqiang Shu; Xiang Liu; Panmei Li; Kunyao Li; Wei Xie; Yaping Zeng; Dechang Peng
Journal:  Front Neurosci       Date:  2022-01-20       Impact factor: 4.677

4.  Functional Connectivity Hypointensity of Middle Cingulate Gyrus and Thalamus in Age-Related Macular Degeneration Patients: A Resting-State Functional Magnetic Resonance Imaging Study.

Authors:  Ang Xiao; Hai-Jun Li; Qiu-Yu Li; Rong-Bin Liang; Hui-Ye Shu; Qian-Min Ge; Xu-Lin Liao; Yi-Cong Pan; Jie-Li Wu; Ting Su; Li-Juan Zhang; Qiong Zhou; Yi Shao
Journal:  Front Aging Neurosci       Date:  2022-03-21       Impact factor: 5.750

5.  Differences in orexin-A level in the functional brain network of HUD patients undergoing harm reduction therapy.

Authors:  Wan-Ru You; Liang-Chun Lin; Wei-Che Lin; Meng-Chang Tsai
Journal:  Medicine (Baltimore)       Date:  2022-08-19       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.